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Background/objectives: The Pediatric Proton Consortium Registry (PPCR) was
established to expedite proton outcomes research in the pediatric population requiring
radiotherapy. Here, we introduce the PPCR as a resource to the oncology community
and provide an overview of the data available for further study and collaboration.
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Design/methods: A multi-institutional registry of integrated clinical, dosimetric, radiographic, and patient-reported data for patients undergoing proton radiation therapy was
conceived in May 2010. Massachusetts General Hospital began enrollment in July of
2012. Subsequently, 12 other institutions joined the PPCR and activated patient accrual,
with the latest joining in 2017. An optional patient-reported quality of life (QoL) survey is
currently implemented at six institutions. Baseline health status, symptoms, medications,
neurocognitive status, audiogram findings, and neuroendocrine testing are collected.
Treatment details of surgery, chemotherapy, and radiation therapy are documented and
radiation plans are archived. Follow-up is collected annually. Data were analyzed 25
September, 2017.

Citation:
Hess CB, Indelicato DJ, Paulino AC,
Hartsell WF, Hill-Kayser CE,
Perkins SM, Mahajan A, Laack NN,
Ermoian RP, Chang AL, Wolden SL,
Mangona VS, Kwok Y, Breneman JC,
Perentesis JP, Gallotto SL,
Weyman EA, Bajaj BVM, Lawell MP,
Yeap BY and Yock TI (2018) An
Update From the Pediatric
Proton Consortium Registry.
Front. Oncol. 8:165.
doi: 10.3389/fonc.2018.00165

results: A total of 1,854 patients have consented and enrolled in the PPCR from October
2012 until September 2017. The cohort is 55% male, 70% Caucasian, and comprised
of 79% United States residents. Central nervous system (CNS) tumors comprise 61%
of the cohort. The most common CNS histologies are as follows: medulloblastoma
(n = 276), ependymoma (n = 214), glioma/astrocytoma (n = 195), craniopharyngioma
(n = 153), and germ cell tumors (n = 108). The most common non-CNS tumors diagnoses are as follows: rhabdomyosarcoma (n = 191), Ewing sarcoma (n = 105), Hodgkin
lymphoma (n = 66), and neuroblastoma (n = 55). The median follow-up is 1.5 years with
a range of 0.14 to 4.6 years.
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INTRODUCTION

Cincinnati Children’s Hospital Medical Center (Cincinnati, OH,
USA). Patient identification, as well as methods for consent,
registration, registry governance, training, site communication,
data oversight, database collection and management, quality
assurance, and preliminary accrual were reported previously
(10). Eligibility criteria include proton treatment at a PPCRactivated institution and age <22 years at the start of radiation
treatment. Patients are permitted to receive concurrent therapy,
to have any type (benign or malignant) or extent (local or metastatic) of disease treated with proton therapy, and to be synchronous participants in other clinical trials, including Children’s
Oncology Group (COG) trials.

Proton therapy is a promising radiotherapy modality that should
reduce toxicity of radiation treatment in children because of its
superior dose placement within intended targets that spares
surrounding normal tissues due to lack of exit dose. On average, it decreases by half the amount of normal tissue treated
compared with modern photon techniques such as intensity
modulated radiation therapy (IMRT) (1, 2). Lower cumulative doses to surrounding normal tissue may mitigate some of
the radiation-related acute and late side effects (3, 4), lessen
toxicity management costs (5, 6), and increase the quality of
life (QoL) in childhood cancer survivors (7, 8). However, the
clinical data supporting the benefits of protons in the pediatric
cancer population are sparse (9). To expedite health outcomes
research in proton radiotherapy for the pediatric population, we
established the Pediatric Proton Consortium Registry (PPCR),
which is currently a collaboration of 13 major pediatric cancer
centers with proton therapy. Here, we report a detailed update
of the largest prospective cohort in existence of children treated
with proton radiotherapy (10). We encourage partnerships
with other investigators to answer health outcomes-based and
comparative-effectiveness questions. We report population
accrual progress, demographics, diagnoses, preliminary vital
status, baseline health information, treatment details, the state
radiographic image and radiation plan archival, and follow-up
for this cohort. We discuss limitations of existing data and future
strategies for optimizing outcome and toxicity reporting.

Registry Infrastructure

Study data are collected and managed using REDCap (Research
Electronic Data Capture) electronic data capture tools hosted at
MGH (https://www.project-redcap.org/). REDCap is a secure,
Health Insurance Portability and Accountability Act (HIPAA)compliant, web-based application designed to support data
capture for research studies created at Vanderbilt University and
supported by the NIH for continuous development and updating to provide infrastructure for clinical research. REDCap
provides (1) an interface for validated data entry, (2) audit
trails for tracking data manipulation and export procedures,
(3) automated export procedures for seamless data downloads
to common statistical packages, and (4) procedures for importing data from external sources (11). The database’s branching
logic enables only fields relevant to the previous answers to
be presented and subsequent questions populated based on
data input. Treatment planning computed tomography (CT)
and radiation therapy (RT) plans are archived in DICOM and
DICOM-RT format, respectively.

MATERIALS AND METHODS
Registry Description

The PPCR is a multi-institutional registry of pediatric patients
treated with proton radiotherapy, established to expedite
research and better define the role of protons in pediatric
care. The consortium of pediatric proton centers is centrally
governed by Massachusetts General Hospital (MGH, Boston,
MA, USA) and includes the following collaborating institutions:
Northwestern Medicine Chicago Proton Center (Chicago, IL,
USA), University of Florida Health Proton Therapy Institute
(Jacksonville, FL, USA), Washington University (St. Louis,
MO, USA), M.D. Anderson Cancer Center (Houston, TX,
USA), University of Pennsylvania (Philadelphia, PA, USA),
University of Washington (Seattle, WA, USA), ProCure Proton
Therapy Center (Somerset, NJ, USA), Mayo Clinic (Rochester,
MN, USA), Procure Proton Therapy Center (Oklahoma City,
OK, USA), Texas Center for Proton Therapy (Irving, TX, USA),
Maryland Proton Therapy Center (Baltimore, MD, USA), and
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Registry Quality Assurance

Multiple quality assurance measures promote and enhance data
completeness, verify data quality, and ensure continual data
collection process improvement. Collaborators receive comprehensive database training prior to activation. Missing Field
Reports are provided at regular intervals to identify critical data
points that may have been left blank in the database. Each site is
provided time to return to the record and enter the missing data,
or justify why it cannot be entered. REDCap’s Data Quality Rules
and Data Queries tools are also utilized to check for and resolve
incorrect data, outliers, and invalid values. All sites are subject to
annual monitoring for validation of data quality and continuity.
Furthermore, the database configuration is routinely examined
and adapted for capture of new or novel data relevant to the aims
of the PPCR.

2

May 2018 | Volume 8 | Article 165

Hess et al.

PPCR Cohort

Figure 1 | Pediatric Proton Consortium Registry (PPCR) enrollment flow diagram.

Table 1 | Pediatric Proton Consortium Registry patient accrual by institution
and date of open enrollment.
Institution

Open to
enrollment

Massachusetts General Hospital (Boston, MA, USA)
Northwestern Medicine Chicago Proton Center
(Chicago, IL, USA)
University of Florida Health Proton Therapy
Institute (Jacksonville, FL, USA)
Washington University (St. Louis, MO, USA)
M.D. Anderson Cancer Center (Houston, TX, USA)
University of Pennsylvania (Philadelphia, PA, USA)
University of Washington (Seattle, WA, USA)
ProCure Proton Therapy Center (Somerset, NJ, USA)
Mayo Clinic (Rochester, MN, USA)
ProCure Proton Therapy Center (Oklahoma City,
OK, USA)
Texas Center for Proton Therapy (Irving, TX, USA)
Maryland Proton Therapy Center (Baltimore, MD, USA)
Cincinnati Children’s Hospital Medical Center
(Cincinnati, OH, USA)

Jul 2012
Sep 2013

478
242

Nov 2013

490

Mar 2014
Jun 2014
Jun 2014
Feb 2016
Jun 2016
Jul 2016
Oct 2016

81
278
89
41
28
58
13

Nov 2016
Apr 2017
Oct 2017

47
9
0

TOTAL

Frontiers in Oncology | www.frontiersin.org

Registry Patient-Reported Outcomes
(PROs)

Patient
accrual

The addition of prospectively collected, PROs was offered to
participating centers in 2015 using a previously validated healthrelated quality of life (HRQoL) survey tool (PedsQL; version 4.0;
generic and fatigue modules). Questionnaires are administered
on a tablet or in paper format in clinic during the first and last
week of radiation treatment and annually thereafter electronically
via REDCap survey sent in an e-mail, or printed on paper if the
participant prefers. The QoL portion of the study was piloted at
MGH before opening to collaborating centers. Five additional
PPCR centers elected to participate in the QoL component of the
study. Follow-up duration was calculated from the time of RT start
for all patients with at least one documented follow-up visit after
a minimum PPCR enrollment period of 1 year. Patients enrolled
within 1 year were excluded from analysis since follow-up data
are collected at 1-year intervals. Totals of certain data categories
may not sum to 100% of cohort because of rounding, missing
data fields, or individual data fields not yet inputted into registry.

1,854
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A thirteenth institution (Cincinnati Children’s Hospital Medical
Center) was added prior to manuscript preparation, but commenced enrollment after data was frozen for analysis. Patients
who were eligible to participate but ultimately did not enroll

RESULTS
As of 25 September, 2017, 1,854 children were enrolled in the
PPCR across 12 actively accruing proton centers nationwide.

Figure 2 | (A) Cumulative Pediatric Proton Consortium Registry (PPCR) accrual across all sites. Accrual represents enrollment by date of consent and
may be larger than total participants within the database at time of analysis. (B) Cumulative PPCR accrual by site.
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follow-up of 1.5 years (range 0.1 to 4.6 years) and 765 (43%) have
available vital status. At the time of reporting, 39 (5.1%) of enrolled
patients were deceased as of their last follow-up (Table 4) and 28
(72%) of these were due to the primary tumor. Three patients
have been taken off study after not re-consenting to participate
at age 18 (12).
At baseline, 88% of patients reported Lansky/Karnofsky
performance status of ≥80. In total, 69% had baseline symptoms,
most commonly focal neurologic findings or visual/ocular abnormalities (Table 5). Of those with available data, 14% reported at
least one comorbidity, the most common being asthma (Table 5).
Roughly one-third of patients reported needing support services
or medical interventions during RT, most commonly including
physical/occupational therapy, feeding tube placement, and
speech or swallow intervention, which differed by institutional
availability of supportive services. Patients commonly reported
use of anti-emetic (27%), antibiotic (25%), and analgesic (22.5%)
medications during treatment. Fourteen percent required pituitary hormonal replacement prior to RT, which was mainly in children with CNS tumors (18.7%) vs. non-CNS (5.8%) (p < 0.0001).
Children with CNS tumors also received more hearing (43% vs.
16%), neurocognitive (31% vs. 4%), and intelligence quotient
(IQ) tests (12% vs. 2%), compared with those with non-CNS
tumors (p < 0.0001 for all) (Table 5).
Two-thirds (66%) of enrolled patients received chemotherapy,
with 59% reporting treatment on or per a COG investigational
protocol. Vincristine, carboplatin, cisplatin, and temozolomide
were the most commonly reported chemotherapeutic agents for
CNS tumors treated outside the auspices of a protocol, while
vincristine, doxorubicin, etoposide, ifosfamide, and cyclophosphamide were most common for non-CNS tumors (Table 6).
Subtotal resections were more common in children with nonCNS tumors (73%) compared with CNS tumors (49%), while
gross total/near resections were less common (27% vs. 51%,
p < 0.0001) (Table 6). A majority of children received curative
craniospinal irradiation (CSI) (17%), or involved field RT (58%)
using mainly passive scattering (68%) vs. pencil-beam scanning
(32%) proton therapy. More children with non-CNS tumors
received pencil-beam scanning (39%) compared with CNS (28%)
(p < 0.0001) (Table 6). At the time of reporting, 734 radiation
plans for 638 patients and 1,690 diagnostic imaging studies for
356 patients have been archived (Table 7).

Table 2 | Pediatric Proton Consortium Registry patient demographics.

Age
Median (years)
Range (years)
≥5 years
<5 years
Gender
Male
Female
Race
Black or African-American
White
Asian
Arab/Middle Eastern
Native American/Alaskan/
Islander
Unknown
Other
Ethnicity: Hispanic
or Latino
Yes
No
Unknown
Residence
International
United States

Total
N = 1,779 (%)*

CNS
N = 1,091 (%)*

Non-CNS
N = 632 (%)*

9.9
0.17–22
1,338 (75.2)
441 (24.8)

9.7
0.17–22
847 (77.6)
244 (22.4)

10.8
0.37–22
454 (68.6)
178 (26.7)

981 (55.3)
793 (44.7)

617 (56.6)
474 (43.4)

333 (52.7)
299 (47.3)

120 (6.7)
1,239 (69.6)
80 (4.5)
27 (1.5)

78 (7.1)
766 (70.2)
54 (5.0)
19 (1.7)

39 (6.2)
442 (69.9)
24 (3.8)
8 (1.3)

14 (<1)
214 (12.0)
62 (3.5)

10 (<1)
119 (10.9)
40 (3.7)

4 (<1)
86 (13.6)
21 (3.3)

190 (11.0)
1,245 (72.2)
290 (16.8)

126 (11.8)
761 (71.5)
177 (16.6)

59 (9.6)
450 (73.2)
106 (17.2)

337 (20.8)
1,285 (79.2)

204 (20.2)
805 (79.8)

127 (22.3)
442 (77.7)

CNS, central nervous system. *Totals may not sum to 100% of cohort because of
rounding, missing data fields, or data not yet inputted into registry. Unavailable data:
CNS category 56/1,779 (3%), gender 5/1,779 (<1%), race 85/1,779 (5%), ethnicity
54/1,779 (3%), and residence 157/1,779 (9%).

on the study were tracked in a separate screening database at
MGH, MD Anderson, Washington University, University of
Florida, ProCure New Jersey, Texas Center for Proton Therapy,
and Maryland. Approximately 347 screened patients from these
seven institutions (mean of 50 per year) declined enrollment
and another 26 initially declined but subsequently agreed to
enroll (Figure 1). Accrual over time for the entire cohort and
by institution is shown in Table 1 and Figures 2A,B. Seventynine percent of the cohort resides in the United States (Table 2,
Figures 3A,B).
Baseline information on 1,779 (96%) participants has been
inputted into the REDCap database, including demographics,
diagnoses, health inventory, prior radiation history, tumorrelated surgical details, diagnostic imaging reports, radiation
treatment details, chemotherapy protocol information, and acute
toxicity. Information from 75 (4%) patients was pending input
completion at the time of data analysis. The cohort is slightly more
male (55%) than female and mainly Caucasian (70%). Median
age is about 10 years and 1 in 5 children are international referrals. Detailed baseline demographic information is described
in Table 2. The most common diagnoses are medulloblastoma,
ependymoma, glial/astrocyte tumors, craniopharyngioma, germ
cell (central nervous system [CNS] tumors), rhabdomyosarcoma,
Ewing sarcoma, Hodgkin lymphoma, and neuroblastoma (nonCNS tumors) (Table 3).
Among patients enrolled prior to September 2016, 888 (50%)
have at least one follow-up visit documented, with a median

Frontiers in Oncology | www.frontiersin.org

DISCUSSION
Registry enrollment of childhood cancer patients receiving pro
ton therapy in the PPCR has reached a critical milestone of over
1,800 children with 1.5-year median follow-up and a variety of
disease types that can now be used for study and comparative
effectiveness analysis with other cohorts.

Vision of the PPCR Cohort

Since cancer occurs much less frequently in children than adults,
collaboration between institutions is very helpful to more quickly
answering important clinical research questions (13). The PPCR
was established to expedite outcomes research in proton therapy
by aggregating sufficient sample sizes of patients treated with
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Figure 3 | (A) Home zip code of children enrolled in the Pediatric Proton Consortium Registry (PPCR) from the United States by treating institution.
(B) Global map of children enrolled in the PPCR by treating institution.

similar tumors with proton radiotherapy across institutions.
While the COG’s collaborative clinical trial infrastructure has
proven itself a model of stepwise clinical advancement and
improving cure rates across diagnoses, randomized prospective
trials are not feasible for many important questions and scenarios
in pediatric oncology (13, 14). Longitudinal cohort studies are
an important adjunct to the randomized trial framework to
help guide and improve treatments when trials are not feasible,

Frontiers in Oncology | www.frontiersin.org

appropriate, or ethical (15–19). Here we describe the PPCR
cohort with baseline demographics, disease information, and
initial follow-up in this relatively young cohort. The PPCR cohort
continues to grow through enrollment and is capable of housing,
collapsing, and categorizing the in-depth health outcomes data
necessary to fully understand the benefits and potential pitfalls of
proton radiotherapy employed in pediatric cancer patients. The
database was designed comprehensively with efficient branching
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Table 3 | Primary diagnosis tumor type.
Intracranial and
CNS tumors

N*

%

Medulloblastoma/
PNET
Ependymoma
Glial/astrocytoma
Tumors/gangliomas
Craniopharyngioma
Germ cell tumor
ATRT

276

25.4

214
195

19.7
18

153
108
27

14.1
9.9
2.5

20
20
18

1.8
1.8
1.7

9
8
7

<1
<1
<1

7
4
2
1

<1
<1
<1
<1

18

1.7

Meningioma
Vascular lesions
Sarcoma
Nerve sheath tumor
Choroid plexus
sPineal parenchymal
tumor
Pituitary tumor
Neurocytoma
Leukemia
Langerhans
histiocytosis
Other

Table 5 | Baseline health information.

Tumors outside
the CNS

N*

%

Rhabdomyosarcoma
(RMS)
Ewing sarcoma
Hodgkin lymphoma

191

30.5

105
66

16.8
10.5

55
47
47

8.8
7.5
7.5

42
11
11

6.7
1.8
1.6

8
6
6

1.3
1.0
1.0

6
4
2
2

1.0
<1
<1
<1

17

2.4

Total*

Hemangioma
Melanoma
Non-Hodgkins lymphoma
Paraganglioma/
Pheochromocytoma
Other

Karnofsky/lansky performance*
≥90
80
70
≤60
Baseline health issues α
None
Focal neurologic issues
Visual/ocular problems
Endocrine abnormality
Emotional/behavioral issues
Speech or swelling deficits
Comorbidities*
At least one comorbidity¥
None reported
Supportive medical services*
At least one utilized§
None reported
Medication during treatment α
None reported
Anti-emetic
Antibiotic
Analgesic
Laxative
Anti-epileptic
Psychotropic
Steroid
Endocrine replacement*
None reported
≥1 hormone replacement†
Baseline Neurocognitive Test*
Obtained
Not obtained/unknown
Baseline audiogram*
Obtained
Not obtained/unknown
Intelligence auotient (FSIQ)β
Obtained
Not obtained/unknown

ATRT, atypical teratoid rhabdoid tumor; CNS, central nervous system; NOS, not
otherwise specified; NRSTS, non-rhabdomyosarcomas soft tissue sarcoma; PNET,
primitive neuroectodermal tumor; RMS, rhabdomyosarcoma. *Totals may not sum
to 100% of cohort because of rounding, missing data fields, or data not yet inputted
into registry. Tumor type not available in 10/1,723 (<1%) of patients with available
diagnostic information [4/1,091 (CNS); 6/632 (non-CNS)]. €Carcinomas include adenoid
cystic, adenocarcinoma, carcinoid, medullary, mucoepidermoid, nasopharyngeal,
neuroendocrine, papillary, sinonasal undifferentiated carcinoma, small cell, squamous
cell, and other.

Table 4 | Clinical and vital status at last follow-up.
CNS

Non-CNS

N(%)
NED/tumor controlled
Alive with disease
Disease progression/recurrence/
transformation
Alive, disease status unknown€
Deceased

559 (73.0)
63 (8.2)
50 (6.5)

364 (73.5)
45 (9.1)
32 (6.5)

195 (72)
18 (6.6)
18 (6.6)

54 (7.1)
39 (5.1)

34 (6.9)
19 (3.8)

20 (7.4)
20 (7.4)

759 (71.8)
175 (16.6)
65 (6.15)
58 (5.45)

460 (67.4)
121(17.7)
50 (7.3)
25(3.66)

298 (79.9)
54 (14.5)
15 (4.02)
6 (1.60)

550 (30.9)
555 (31.2)
292 (16.4)
137 (7.7)
132 (7.4)
120 (6.7)

266 (24.8)
462 (42.4)
237 (21.7)
122 (11.2)
92 (8.4)
95 (8.7)

284 (44.9)
93 (14.0)
54 (8.5)
15 (2.4)
40 (6.3)
25 (4.0)

203 (14.3)
1,212 (85.7)

125(14.0)
774 (86.1)

78 (15.1)
437 (84.9)

414 (31.4)
903 (68.6)

289 (34.4)
551 (65.6)

125 (26.3)
351 (73.7)

312 (17.5)
480 (27.0)
444 (25.0)
401 (22.5)
294 (16.5)
182 (10.2)
179 (10.1)
130 (7.31)

236 (21.6)
243 (22.3)
172 (15.8)
236 (21.6)
143 (13.1)
153 (14.0)
100 (9.2)
100 (9.2)

76 (12.0)
237 (37.5)
272 (43.04)
165 (26.1)
151 (23.9)
29 (4.6)
79 (12.5)
30 (4.8)

1,121(85.8)
186 (14.2)

686 (81.3)
158 (18.7)

435 (94.2)
27 (5.8)

303 (21.3)
1,119 (78.7)

281 (31.2)
619 (68.8)

22 (4.2)
499 (95.7)

468 (40.5)
957 (82.9)

|386 (42.8)
516 (57.2)

82 (15.7)
439 (84.3)

143 (8.0)
1,636 (92.0)

131 (12.0)
960 (88.0)

12 (1.9)
620 (98.1)

CNS, central nervous system; FSIQ, Full Scale Intelligence Quotient; NOS, not
otherwise specified. *Totals may not sum to 100% of cohort because of rounding,
missing data fields, or data not yet inputted into registry. Unavailable data: performance
status 722/1,779 (41%), comorbidities 364/1,779 (20.5%), supportive medical services
462/1,779 (26.0%), endocrine replacement 472/1,779 (26.5%), neurocognitive
testing 357/1,779 (20%), and audiology 354/1,779 (20%). βProportion of missing data
unavailable for intelligent quotient. αTotals and percentages of baseline health issues
and medication during treatment reflect occurrence within the registry and may exceed
100 due to multiple responses per patient. ¥Common reported comorbidities include
asthma 92/203 (45.3% of reported comorbidities), diabetes mellitus 28/203 (13.8%),
and primary tumor of a different histology 10/203 (4.9%). §Common supportive services
include physical/occupational therapy 182/414 (44.0% of reported services), gastric
feeding tubes 157/414 (37.9%), and speech and swallow therapy 72/414 (17.4%).
†
Among patients with replaced hormones at the time of enrollment: thyroid 122/186
(65.6%), desmopressin 107/186 (57.5%), cortisol 99/186 (53.2%), growth 16/186
(8.6%), and sex hormones 19/186 (10.2%).

CNS, central nervous system; NED, no evidence of disease. *Totals may not sum to
100% of cohort because of rounding, missing data fields, or data not yet inputted into
registry. Unavailable data: vital status 1,014/1,779 (57%) of patients. €Alive, but no
information about disease status available.

logic. However, the REDCap platform also allows flexible adaptation of data fields as needed. This registry is established to
be a resource for participating investigators as well as outside
researchers seeking to answer important health outcomes questions in this pediatric population.

and offered recommendations on next best steps to ensure the
PPCR’s long-term investigational success. Their recommen
dations have been incorporated into the following PPCR strate
gic multiphase implementation plan: (1) define and fill critical
missing data fields, (2) retrospectively expand the cohort to
enroll all patients previously treated since the opening of

Next Steps Toward Comparative Research

In May 2017, an External Advisory Board to the PPCR convened, consisting of leaders in the pediatric oncology and
radiation oncology communities and epidemiological research,

Frontiers in Oncology | www.frontiersin.org

Non-CNS

N (%)

Neuroblastoma
Chordoma
Non-rms soft tissue
sarcomas (NRSTS)
Carcinoma (NOS)€
Retinoblastoma
Osteosarcoma/bone
sarcoma
Chondrosarcoma
Esthesioneuroblastoma
Wilms tumor

Total*

CNS
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Table 6 | Information on treatments in addition to radiation.
Total*
Chemotherapy *

CNS

Table 7 | Radiation treatment.
Non-CNS

Total

N(%)

Not received
Received
Patients receiving chemo
on or per COG Trial€

476 (34.4)
908 (65.6)
498 (59.2)

389 (44.4)
487 (55.6)
249 (55.3)

Vincristine
Etoposide
Cyclophosphamide
Carboplatin
Doxorubicin
Ifosfamide
Cisplatin
Temozolomide
Methotrexate
Bevacizumab
Thiotepa
Actinomycin D
Irinotecan

194 (56.6)
117 (34.1)
104 (30.3)
83 (24.2)
77 (22.5)
67 (19.5)
63 (18.4)
53 (15.5)
30 (8.8)
18 (5.3)
14 (4.1)
16 (4.7)
8 (2.3)

112 (55.7)
54 (26.9)
47 (23.4)
64 (31.8)
7 (3.5)
17 (8.5)
44 (21.9)
44 (21.9)
25 (12.4)
15 (7.5)
14 (7.0)
3 (1.5)
3 (1.5)

86 (17.0)
421 (83.0)
249 (63.7)

Intent of RT*
Curative
Palliative
Source/technique received*α
Photons
Electrons
Protons
Area treated*α
CSI
IF
PF
Whole ventricle
Whole brain
Whole lung
Pelvic field
Other
Proton modality*
Passive scatter
Pencil beam (IMPT)

82 (57.6)
63 (44.4)
57 (40.1)
19 (13.4)
70 (49.3)
50 (40.1)
19 (13.4)
9 (6.3)
5 (3.5)
3 (2.1)
0
13 (9.2)
5 (3.5)

506 (41.3)
121 (9.9)
597 (48.8)

142 (20.5)
47 (6.8)
505 (72.8)

COG, Children’s Oncology Group; CNS, central nervous system; GTR, gross total
resection; NOS, not otherwise specified; NTR, near total resection; STR, subtotal
resection. *Totals may not sum to 100% of cohort because of rounding, missing data
fields, or data not yet inputted into registry. Unavailable data: chemotherapy 395/1,779
(22.2%), resection status 463/1,779 (26.0%). αTotals and percentages of common
chemotherapy agents and pretreatment surgery results reflect occurrence within
the registry and may exceed 100 due to multiple responses per patient. €Percent
patients receiving chemotherapy on or per COG trial out of those who received any
chemotherapy either before, during, or after radiation treatment (N = 908). ¥Percent
of total, CNS, and non-CNS patients who received chemotherapy at any time point
not associated with a COG trial.

874 (98.8)
11 (1.2)

498 (98.6)
7 (1.4)

118 (7.7)
4 (<1)
1,416 (92.1)

51 (5.4)
2 (<1)
894 (94.4)

65 (11.2)
2 (<1)
515 (88.5)

269 (17.0)
919 (58.2)
140 (8.9)
48 (3.0)
19 (1.2)
5 (<1)
49 (3.1)
131 (8.3)

263 (24.7)
549 (51.5)
137 (12.8)
48 (4.5)
18 (1.7)
0 (0)
1 (<1)
51 (4.8)

6 (1.2)
370 (72.3)
3 (<1)
0 (0)
1 (<1)
5 (1)
48 (9.4)
79 (15.4)

937 (67.9)
443 (32.1)

630 (72.0)
245 (28.0)

306 (60.7)
198 (39.3)

are in process to automate and address the costs of manual data
entry (21). Institutional processes for re-consenting minors for
registry participation at the age of majority are being revised to
maintain participants into adulthood (see Section “Re-Consenting
at the Age of Majority”) (12). Integrated sharing of and enhanced
access to electronic medical records across member institutions
is lowering the burden of obtaining follow-up records (22).
Ongoing improvements to the database platform are being made
to increase efficiency in data collection. For example, analysis
of the medication free-text data field led to the integration of
common write-in medications in drop-down menus, including
proton pump inhibitors (omeprazole), multivitamins, bonemarrow stimulants (filgrastim, pegfilgrastim), melatonin, and
anti-allergens (cetirizine, loratadine). Adding these drugs to the
check list reduces the time required to enter data and limits the
amount of free text to analyze. These lessons, and those learned by
other registry efforts provide modernization strategies for other
researchers (23).

each member institution (roughly 2006) and improve existing
patient engagement, and (3) promote investigator-initiated use
of the cohort to study the various facets of outcomes research
to further promote and grow PPCR resources. These next steps
will improve the quality of PPCR data available for comparison
with contemporary photon cohorts to better determine who is
getting proton RT and delineate its benefits (13, 20). This data
resource will be made available to all academic investigators
through partnerships with existing PPCR member institutions
and a proposal review process similar to other cohort studies*. At present, a point of contact is available for interested
collaborators**.
Challenges and Modernization
The PPCR opened in 2012 with funding support from the
Clinical Radiation Oncology Branch of National Cancer Institute
(NCI). These funds, derived from the NCI/MGH Federal Share
of Proton Income, are due to end in 2019. Efforts to modernize
the registry are actively being pursued to increase efficiency and
sustainability. The role of patient (and parent proxy) reported
outcomes is expanding to more efficiently gather in-depth data
from the medical record when patients self-report health changes.
Collaborations with natural language processing (NLP) scientists

Frontiers in Oncology | www.frontiersin.org

1,378 (98.7)
18 (1.3)

CSI, cranial spatial irradiation; IF, involved field; PF, posterior fossa; IMPT, intensitymodulated proton therapy; RT, radiation therapy. *Totals may not sum to 100%
of cohort because of rounding, missing data fields, or data not yet inputted into
registry. Unavailable data: intent of RT 383/1,779 (21.5%), source/technique received
121/1,779 (6.8%), area treated 147/1,779 (8.3%), and proton modality 399/1,779
(22.4%). α Totals and percentages of source/technique received and area-treated
reflect occurrence within the registry and may exceed 100 due to multiple responses
per patient.

Pre-treatment surgery results*α
648 (33.8)
168 (8.8)
1,102 (57.5)

Non-CNS

N(%)

Common chemotherapy agents (not associated with a trial) α ¥

Gross total (GTR)
Near total (NTR)
Subtotal (STR)/Biopsy

CNS

Re-Consenting at the Age of Majority

Pediatric Proton Consortium Registry participants are commonly treated at tertiary or quaternary referral proton centers
but receive follow-up care with primary providers closer to their
home. When participants reach the age of majority, re-consent
for study enrollment is required. Prior Institutional Review Board
(IRB) regulations at the lead site required the study team to make
three attempts to reconsent the patient, and if no response was
received, the participant was removed from the study as of their
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18th birthday. As of December 2016, 28 participants reached
adulthood at Mass General, 6 reconsented, 2 declined, and 20
did not respond. The MGH IRB approved a change of this policy
to include an HIPAA waiver for this minimal risk data collection
study. Participants now opt in or out as adults, and if no response
is received, they remain enrolled on the study (12). Each site
follows its own institutional IRB guidelines about re-consenting
patients at the age of majority.

ETHICS STATEMENT

Broader Data Quality Monitoring

Investigation: DI, AP, WH, CH-K, SP, AM, NL, RE, AC, SW, VM,
YK, JB, JP, and TY. Formal analysis: CH, BB, BY, and TY. Funding
acquisition: CH, SG, EW, BB, and TY. Project administration: SG,
EW, ML, and TY. Resources: DI, AP, WH, CH-K, SP, AM, NL,
RE, AC, SW, VM, YK, JB, JP, and TY. Writing—original draft
preparation: CH, SG, EW, BB, ML, and TY. Writing—review and
editing: all authors.

This study includes children and was reviewed and approved
by the Institutional Review Board at Massachusetts General
Hospital and at all 13 participating registry sites. All patients were
consented for registry participation.

AUTHOR CONTRIBUTIONS

Oversight monitoring of member institutions was first initiated
in the PPCR at a level of scrutiny akin to that of a multicenter
clinical trial and was later de-intensified to reflect the nomore-than-minimal risk nature of the registry. Costs of annual
travel for external patient audits grew prohibitively large with
incremental growth to 13 member institutions. These costs,
balanced by the need to ensure data completeness, led to the
central PPCR team to assume multicenter responsibilities
and remotely monitor data completeness without required
travel. Key fields were identified and targeted for review and
routine remote correspondence is conducted with each site for
incomplete data inquiries. Data incompleteness was associated
with a temporary lapse in registry funding that is actively being
addressed (24).
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